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Introdu on: Women with a strong family history of breast cancer (BC) and without a known 
gene muta on have an increased risk of developing BC. We aimed to inves gate the accuracy 
of screening using annual mammography with or without magne c resonance imaging (MRI) 
for these women outside the general popula on screening program. 
1
Methods: An individual pa ent data (IPD) meta-analysis was conducted using IPD from six 
prospec ve screening trials that had included women at increased risk for BC: only women 
with a strong familial risk for BC and without a known gene muta on were included in this 
analysis. A generalised linear mixed model was applied to es mate and compare screening 
accuracy (sensi vity, speciﬁcity and predic ve values) for annual mammography with or 
without MRI.
1
Results: There were 2,226 women (median age: 41 years, interquar le range 35.3-47) with 
7,478 woman-years of follow-up, with a BC rate of 11.6 (95% conﬁdence interval 9.3-14.4) in 
1,000 woman-years. Mammography screening had a sensi vity of 55.1% (standard error of 
mean [SE] 7.0) and a speciﬁcity of 93.7% (SE 1.3). Screening with MRI alone had a sensi vity of 
89.3% (SE 4.6) and a speciﬁcity of 82.9% (SE 2.8). Adding MRI to mammography increased 
sensi vity to 98.4% (SE 1.8, P<0.01 compared to mammography alone) but lowered 
speciﬁcity to 78.9% (SE 2.7, P<0.01 compared with mammography alone). 
1
Conclusion: In this popula on of women with strong familial BC risk but without a known 
gene muta on, in whom BC incidence was high both before and a er age 50, adding MRI to 
mammography substan ally increased screening sensi vity but also decreased its speciﬁcity.
1
Highlights
 In women at familial risk and no known muta ons, we es mate a breast cancer (BC) rate of 
12 per 1000 woman-years.
1
 BC rate increased from 5.1 per 1000 in women <40 years to 21 per 1000 in women >50 
years.
1
 Mammography sensi vity ranged from 51% in women <40 to 67% in women ≥50 years.
1






About 15-20% of breast cancer (BC) cases are associated with a family history of BC (1) . 
Women without a known muta on in a hereditary BC gene, but with a family history of breast 
with/without ovarian cancer, are at a higher risk of developing BC, the extent of the increased 
risk depends on the number of aﬀected rela ves and the age at cancer diagnosis in the 
rela ve(s) (2,3) . These women at familial risk, who have a cumula ve life me risk of 
developing BC over 15% to 20%, are usually oﬀered a BC screening regimen outside of the 
general popula on screening program, star ng at an earlier age and including more frequent 
(annual) mammography (4,5) .
Results of many prospec ve trials evalua ng the accuracy of adding annual MRI to 
mammography for screening these women have been published (6-15). Although these 
studies emphasised the signiﬁcantly greater sensi vity of annual magne c resonance 
imaging (MRI) and mammography in combina on for screening this high-risk popula on, 
several issues remain unclear. First, inclusion criteria were heterogeneous and all the studies 
also included women with known gene muta ons. Furthermore, the deﬁni on of familial risk 
for BC varied across countries and centres depending on referral criteria and risk assessment 
tools. Also, few studies reported results separately for women at familial risk without a known 
gene muta on  (8)(11,12) and none of the studies reported results stra ﬁed by age for this 
popula on. 
In this meta-analysis, pooling individual pa ent data (IPD) from prospec ve trials, we aimed 
to assess the accuracy of screening women at familial risk of BC without a known gene 





An IPD meta-analysis was conducted including individual data from 6 of 12 prospec ve trials 
in which women at high risk of BC due to an inherited BRCA gene muta on or a strong family 
history of BC were screened with annual mammography and MRI, and the accuracy of each 
screening modality was reported separately (16,17). All studies were performed in developed 
countries. More details about the study inclusion criteria, data acquisi on and assembly and 
quality assessment were reported in our previous publica on which focused on BRCA1/2 
gene muta on carriers (17). In the present study, we focus only on women with a strong 
family history of BC (deﬁned as a cumula ve life me BC risk of at least 15%) and without a 
Chapter	5 MRI	and	mammography	screening	in	women	at	familial	risk
125
known gene muta on. Speciﬁc inclusion criteria for the original studies contribu ng to this 
IPD meta-analysis, outlining family history criteria and whether women with a personal 
history of BC were included are summarised in Supplementary appendix 1. 
Study popula on 
1
Women aged 25 or older who had a strong family history of BC and no known gene muta on 
and had completed at least one screening round, were included in this analysis. A completed 
screening round was deﬁned as a screening round in which both MRI and mammography 
were performed within a  me interval of less than 3 months, with results of the two tests 
interpreted separately using blinded methods. Screens were included if there was either a 
pathology test or at least 1 year follow-up to conﬁrm the presence or absence of BC. Women 
who were proven to be non-muta on carriers from a BRCA family were excluded, as their risk 
is generally considered to be comparable to that of the general popula on. Screen-detected 
or interval cancers were counted in this analysis (BCs found during preven ve mastectomy 
were not considered).
Primary outcome and deﬁni ons
1
Primary outcomes were screening accuracy including sensi vity, speciﬁcity and 
posi ve/nega ve predic ve value (PPV/NPV). To adjust for mul ple screenings of the same 
women and diﬀerences between studies, the es mates for each modality were model-based 
with the following: (1) sensi vity deﬁned as the number of BCs detected over the total 
number of BC diagnosed; (2) speciﬁcity deﬁned as the number of true-nega ve tests over the 
total number of screens without BC; (3) PPV deﬁned as the number of true-posi ve over the 
total number of posi ve tests; (4) NPV as the number of true-nega ves over the total number 
of nega ve tests. 
 Imaging scores of BI-RADS 0, 3, 4 or 5 (Breast imaging-repor ng and data system) 
were considered to be a posi ve screening result. Using this threshold allowed harmonisa on 
of the outcomes across studies. The combina on of MRI and mammography was classiﬁed as 
a posi ve result if either one of these tests was posi ve. BI-RADS 1 or 2 was considered a 
nega ve test, and a nega ve outcome of the combina on was based on both tests having 
nega ve results. For posi ve test results, the presence of BC was based on the results of 
histologic examina on. The absence of BC was ascertained by histologic examina on or 1 
year follow-up with nega ve screening or stable imaging. Where more than one tumour was 
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diagnosed in a woman in the same screening round, the largest BC was included. Where more 
than one BC was diagnosed in a woman at diﬀerent screening years, the ﬁrst BC was included. 
For analy c purposes, a BC was considered an interval cancer when it was not detected by a 
posi ve screening test (mammography or MRI) and was diagnosed between two annual 
rounds of screening. The above deﬁni ons were applied to all the studies when assembling 
the individual data to obtain consistency and comparable data from all studies, although 
there were slight diﬀerences between these deﬁni ons and the deﬁni ons that may have 
been applied in the original studies. 
Sta s cal analysis
1
Characteris cs of the women (follow-up  me, cancer incidence, median age at entry with 
interquar le range [IQR]) and cancer characteris cs were reported for the total study 
popula on and for each age-group. Overall cancer incidence in total and stra fying by 
screening round, were calculated as the number of BCs per 10,000 woman-years and the 95% 
conﬁdence interval (CI) was computed assuming the incidence follows a Poisson distribu on. 
 A generalised linear mixed model (Procedure Glimmix using the QUAD op on for the 
likelihood method of es ma on the binomial distribu on with logit link func on, SAS version 
9.4) was applied to es mate sensi vity, speciﬁcity and the predic ve values of each screening 
modality and then compare these measures for the two screening modali es and the 
combina on using Wald tests. One analysis is done for sensi vity and speciﬁcity 
simultaneously and another for predic ve values. For sensi vity and speciﬁcity, repeated 
measurements were summarised for each woman to the total number of screens with proven 
BC, total number of screens without BC, the number of true-posi ves and the number of true-
nega ves. Each woman had six records: two ascertained outcomes (with or without proven 
BC) for each of three screening modali es (mammography, MRI and the combina on).In the 
model, the numbers of true-posi ve/nega ve tests followed a binomial distribu on with the 
total number of screens with/ without proven BCs and a propor on that was modelled as a 
func on of screening modality. To address heterogeneity between studies, a bivariate 
random variable with an unstructured correla on matrix was added to model the study eﬀect 
for each screening modality and each ascertained outcome. Analysis was performed for each 
age-group separately. Sensi vity and speciﬁcity were modelled simultaneously to take into 
account their nega ve correla on. The same approach was used for posi ve and NPVs by 
replacing the ascertained outcomes by modality outcomes (test posi ve or nega ve) and 
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posi ve or nega ve) and number of screens with/without BCs by the number of screens with 
posi ve/nega ve test. Screening accuracy for the three modali es was compared within age-
groups deﬁned by age at screening, as follows: younger than 40 years, 40-49 years and 50 
years and older. In two sensi vity analyses, the year of screening was added to the model to 
explore its impact on the results, and screening accuracy was es mated for ﬁrst and 
subsequent rounds to allow for prevalent cases. 
Results 
Study popula on and breast cancers during the study 
1
Data on 2,226 women at familial risk with at least one completed screening round were 
included in this analysis, represen ng 7,478 woman-years of follow-up (median 3 years, IQR 
2-5) with ascertained outcomes (Table 1). There were 106 (4.8%) women with a personal 
history of BC and 193 (8.7%) women with a nega ve gene c test result. Amongst these 2,226 
women with a median age of 41 years (IQR 35.3-47) at study entry, 87 BCs were diagnosed at a 
median age of 48.4 (IQR 42.6-54) years. BC rate was es mated as 11.6 (95%CI 9.3-14.4) per 
1,000 woman-years. BC incidence increased with increasing age: 5.1 (95%CI 2.8-8.6) per 
1,000 woman-years in women who underwent screening before age 40, 11.9 (95%CI 8.3-
16.4) per 1,000 woman-years in women aged 40-49, and 21.6 (95%CI 15.2-29.8) per 1,000 
woman-years in women aged 50 and older. Of all BCs, 37 were prevalent cancers (detected at 
the ﬁrst screening round); excluding those prevalent cancers the rate (per 1,000 woman-
years) was 9.5 (95%CI 7.1-12.6) in all women, 5.7 (95%CI 2.7-10.5) in women aged <40, 8.3 
(95%CI 4.9-13) in women aged 40-50 and 16.6 (95%CI 10.4 – 25.1) in women aged >50. 
Amongst 87 BCs observed in the study popula on, three were interval cancers: all were 
invasive, smaller than 2cm, and diagnosed in women aged 37, 46 and 57 years. The youngest 
group had more invasive BCs and more large invasive BCs than the older age group (Table 1).  
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Table 1: Overview of the women at familial risk and their breast cancers characteris cs, 
stra fying by age at screening (N=2,226; BCs=87) 
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Table 2: Screening accuracy in women at familial risk of breast cancer (N=2,226, BCs=87, 
median screening rounds: 3 [IQR 2-5])
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Screening accuracy in all women 
In the total study popula on, mammography sensi vity was 55.1% (standard error of mean 
[SE] 7.0) (Table 2). The combina on of MRI and mammography had the highest sensi vity but 
the lowest speciﬁcity. The combined sensi vity was 98.4% (SE 1.8) versus 89.3% (SE 4.6) for 
MRI alone (P<0.001) and 55.1% (SE 7.0) for mammography alone (P<0.001). The combina on 
had the lowest speciﬁcity of 78.9% (SE 2.7) versus 82.9% (SE 2.8) for MRI alone (P<0.01) and 
93.7% (SE 1.3) for mammography alone (P<0.01). The PPVs of the three screening modali es 
were generally comparable around 9%, whereas diﬀerences were observed for NPVs, as 
summarised in Table 2. When adjus ng for year at screening (results not shown) or excluding 
the ﬁrst screening round (Table 4), the es mates for sensi vity and speciﬁcity did not change. 
PPV: posi ve predic ve value; NPV: nega ve predic ve value; SE: Standard error of mean
*Compared to the combina on sensi vity: P=0.0008; **Compared to the combina on sensi vity: P<0.0001;
µ Compared to the combina on speciﬁcity: P=0.002; ¥ Compare to the combina on speciﬁcity: P=0.002; 
α Compared to the combina on NPV: P= 0.001; β Compared to the combina on NPV: P= 0.0002; 
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Table 2: Screening accuracy in women at familial risk of breast cancer (N=2,226, BCs=87, 
median screening rounds: 3 [IQR 2-5])
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PPV: posi ve predic ve value; NPV: nega ve predic ve value; SR: screening round, median and interquar le range; 
SE: Standard error of mean
*Compared to the combina on sensi vity: P=0.003; **Compared to the combina on sensi vity: P=0.002;
α Compared to the combina on speciﬁcity; P=0.04
¥Compared to the combina on sensi vity: P=0.003;π Compared to the combina on sensi vity: P<0.0001;
ᵟ Compared to the combina on speciﬁcity; P=0.006; β Compared to the combina on NPV: P=0.02
£Compared to the combina on sensi vity: P=0.0003; µ Compared to the combina on speciﬁcity: P=0.03; 
& Compared to the combina on NPV: P=0.02; 
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Cancer detec on: contribu on of screening modali es in diﬀerent age groups
5
Screening with the combina on of MRI and mammography had higher sensi vity compared 
with mammography alone in all age groups (Table 2). In women younger than 40 years, the 
sensi vity of the combina on was 95.4% (SE 5.6) versus 51% (SE 13.4) for mammography 
(P<0.01) and MRI alone detected seven invasive cancers (of 14 cancers, 50%, four invasive 
tumours 1-2cm), which were not detected at mammography (Table 3). In women aged 40-49, 
the sensi vity of the combina on was 98.4% (SE 2) compared to mammography sensi vity 
57.2% (SE 8.2, P<0.01) (Table 3) and MRI detected 17 cancers (of 36 cancers, 47.2%) which 
were not detected at mammography, among which 12 were invasive cancers (six tumours 
were ≤1cm), four were ductal carcinoma in situ (DCIS) and one was unspeciﬁed. In women ≥ 
50, sensi vity of the combina on was 97.4% (SE 3.0) (compared to 66.6%, SE 7.8 P>0.05, for 
mammography), and MRI alone detected 12 cancers (of 37 cancers, 32.4%, including two 
cases of DCIS and one invasive tumour ≤1cm) that were not detected by mammography 
(Table 3). 
1
 The sensi vity of mammography improved to some extent with increasing age. The 
sensi vity of mammography was low in women <40 years (51% SE 13.4) (Table 3). In the 
women < 40 years, mammography visualised six of 14 cancers and only for one case, the 
tumour (DCIS) would have been missed if mammography would not have been performed. In 
women age 40-49, mammography sensi vity was 57.2% (SE 8.2). In this age-group, 18 of 35 
cancers could be visualised with mammography, and four cancers (three DCIS and one 
invasive ≤1cm) were missed by MRI (Table 3). In women aged >=50, mammography had a 
sensi vity of 66.6% (SE 7.8) (Table 3). Mammography visualised 24 of 37 cancers and four of 
those (one DCIS and three invasive) were not detected by MRI. 
Predic ve value of screening modali es in diﬀerent age groups 
1
The PPV of each modality increased by age, whereas the NPV remained at about 99% or 
higher: Details are shown in Table 3. 
Discussion
1
Our IPD meta-analysis examined the accuracy of screening mammography with or without MRI in 
women with a strong family history of BC and without a known gene muta on: Based on data for 2,226 
women, the observed BC incidence rate was high (11.6 per 1,000 woman-years) and this was evident in 
both younger and older women, highligh ng the BC burden in this popula on. The sensi vity of 
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Table 4: Screening accuracy in women at familial risk of breast cancer, stra ﬁed by screening rounds
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TP: true posi ve; TN: true nega ve; FP: false posi ve; FN: false nega ve;  SE: standard error of mean
*compare to the combina on: p<0.01
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mammography was only 55.1% (SE 7.0). However, mammography was the most speciﬁc 
modality compared to MRI alone or the combina on of MRI and mammography. Combining 
MRI and mammography detected the great majority of cancers with a sensi vity of 98%, 
signiﬁcantly higher than the 55.1% sensi vity of mammography or 89% of MRI alone 
(P<0.001). The higher sensi vity of the combina on of mammography and MRI was evident 
in all age groups. The combina on, however, had the lowest speciﬁcity due to a rela vely high 
number of false-posi ves from MRI. 
1
 The accuracy of screening mammography for women at elevated risk due to family 
history and without a proven muta on was examined in some of the original primary studies 
contribu ng data for this IPD meta-analysis, and the results were generally comparable to this 
IPD meta-analysis, though based on fewer cases. Of those eligible studies that did not 
par cipate in this IPD meta-analysis (6,7,9,10,18) , one study reported a low mammography 
sensi vity (25%) in women with an es mated life me BC risk of 21-40%  . Another study 
reported that mammography detected two of four BCs in 142 women with > 25% life me risk 
of developing BC (18). Although outside the scope of this IPD, a prospec ve screening study 
including women (mean age 55, range 25-91) at familial risk and who had heterogeneously 
dense or extremely dense parenchyma reported a mammography sensi vity of 50% (95%CI 
33.8-66.2) (19). Another retrospec ve study showed that annual mammography did not 
contribute to cancer detec on over annual MRI in a retrospec ve cohort of women younger 
than 40 years with a life me risk of more than 20%, in whom four BCs were diagnosed (20). 
Similarly, our IPD meta-analysis showed that mammography sensi vity was rela vely modest 
(51% [SE 7.0]) whereas adding MRI increased the sensi vity up to 95.4% (SE 1.8). 
1
Adding MRI screening has been shown to improve screening accuracy compared to 
mammography alone in other popula ons at increased BC risk, speciﬁcally in women with 
BRCA1/2 muta on (16). However, adding MRI to mammography gave a signiﬁcantly higher 
number of false-posi ve results. In addi on, adding MRI is costly. It should be noted that in 
these studies, MRI and mammography were performed and interpreted independently, and a 
posi ve result was referred to whenever either test was posi ve joint interpreta on may 
poten ally help reduce the number of false posi ves. Yet there s ll remains a lack of evidence 
regarding the long term eﬀects of annual MRI plus mammography compared with annual 
mammography.
1
The strength of this IPD meta-analysis is that it collected individual data from six prospec ve 
screening studies, crea ng the ﬁrst pooled analysis of women with strong family history and 
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without a known gene muta on. Further, it allowed implementa on of common deﬁni ons 
and thresholds as well as subgroup analyses, through the collec ve datasets and through the 
use of IPD methodology. Nonetheless, there are several limita ons to this meta-analysis. 
First, the number of women and cancers in some subgroup analyses remained too small to 
obtain either a clear trend or sta s cal signiﬁcance. Second, we might have underes mated 
the accuracy of screening because the data collected in these studies are based on rela vely 
older imaging technology (17). Although we explored this issue by adding year of screening to 
our model and found that it did not substan ally change the es mates for sensi vity and 
speciﬁcity. We acknowledge that higher accuracy may be expected for current 
mammography and MRI technology, due to improved MRI technology (21,22) , be er deﬁned 
MRI BI-RADS descriptors and diagnos c categories (23)  and the increasing use of breast 
digital tomosynthesis for screening  (24,25). Third, we included IPD from six prospec ve 
screening trials, yet each original study had its own recruitment  me frame, age at 
recruitment, inclusion criteria and risk assessment tool for women without a proven 
muta on (Supplementary 1); thus, there was unavoidable heterogeneity in the format for 
family history data and probably risk level, reﬂec ng real-life prac ces. It was therefore not 
possible to es mate BC risk for all the study popula on using one common criterion or 
assessment model without making some assump ons. In addi on, despite some small 
diﬀerences between countries, the overall life me risk to develop BC in countries where the 
included studies were performed is 1 in 8 (26,27), which is not expected to have any impact on 
the here presented results on compara ve accuracy. Furthermore, there was no informa on 
about CHEK2 prevalence in these cohorts, and the eﬀect of this gene muta on in screening 
accuracy was not examined. Future research focussing on the burden of family history and 
other gene muta ons may poten ally help reﬁne and personalise screening strategies in 
these women. Finally, as the included studies inves gated screening accuracy and did not 
report data on long-term outcomes such as survival, we could not include such outcomes in 
our analysis.
Our IPD meta-analysis highlights that adding MRI to mammography signiﬁcantly improves BC 
detec on in women with a strong family history of BC and without known gene muta ons; 
however this should be considered against the higher false-posi ve rate (lower speciﬁcity) 
caused by adding MRI screening. Our ﬁndings might lead to the conclusion that MRI screening 
alone may be appropriate for these women; however, compara ve accuracy studies, such as 
reported in this work, need to be complemented by health-economic evalua on to 
determine whether such an approach could be cost-eﬀec ve. Also, future research in this 
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research in this popula on of women is cri cally needed to examine alternate screening 
approaches, inves ga ng new, faster (and less costly) MRI techniques and tomosynthesis as a 
replacement for 2-D mammography to develop screening strategies that op mise BC 
detec on without signiﬁcantly increasing the false-posi ve recall burden.
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Number of women (N)/
 





Age at recruitment (median, 
IQR)  
Gene c status (%)  
Inclusion criteria
 
MRISC study (12)  
N=1,426  
BCs=38 *  
Time frame: 11/1999-3/2006  
Age: 40 [34-47]  
Nega ve tes ng: 0%  
Unknown muta on: 100%  
Women at high risk (cumula ve life me risk 30-50%) 
according to modiﬁed Claus model, deﬁned as women who 
have at least one of the following criteria: 
+ A ﬁrst-degree family member with a BRCA1/2 
muta on 
+ A ﬁrst-degree-family member and two other ﬁrst 
or second degree family members aﬀected with 
breast or ovarian cancer 
+ Two ﬁrst-degree or one ﬁrst and one second-
degree family members with breast cancer, mean 
age at diagnosis 45 years or younger. 
 
Or women at moderate risk (cumula ve life me risk 15-30%) 
according to modiﬁed Claus model, deﬁned as women who 
have at  least one of the following criteria: 
+ A second-degree family member with a BRCA1/2 
muta on. 
+ One ﬁrst-degree family member with breast cancer 
younger than 40 years 
+ Two ﬁrst-degree family members or one ﬁrst- and 
one second degree family member with breast 
cancer together, mean age at diagnosis between 45 
and 60 years. 
+ Three second-degree family members with breast 
or ovarian cancer 
+ Two ﬁrst or one ﬁrst and one second-degree family 
members, 1 aﬀected with breast cancer younger 




















Unknown muta on: 81%  




+ Three or more rela ves on the same side of the 
family with breast cancer diagnosed before the age 
of 61 or one rela ve diagnosed with ovarian cancer 
at any age, 
+ Two or more rela ves on the same side of the 
family with breast cancer diagnosed before the age 
of 51 or one rela ve diagnosed with ovarian cancer 
at any age, and  
+ Rela ve with breast cancer diagnosed before the 
age of 36.  
In any case, the women had to be a ﬁrst-degree 
rela ve of one of the aﬀected rela ves or be one of 
the aﬀected herself.  
 
Exclude women who were proved not to be carriers in a family 
with a proven muta on because their breast cancer risk was 
not assumed to be elevated; women with clinical signs of 
breast  cancer at their ﬁrst visit were also excluded but became 
eligible to par cipate 1 year a er treatment. 
MARIB study (8)  
N=452  
BCs=8  
Time frame: 8/1997-5/2004  
Age: 40 [37-44.5]  
Nega ve tes ng: 0%  
Unknown muta on: 100%  
Women age 35-49 who have at least one of following criteria: 
 
+ At 50% risk of being carrier because of known 
muta on in parent or sibling, or 
+ At a 50% risk of carrying BRCA1/2 because of 
family history: having 4 or more cases of female 
breast cancer below the age of 60; or having 4 or 
more cases of female breast and ovarian cancer 
where the breast cancer is below the age of 60 and 
the ovarian cancer is at any age; or having 4 or more 
cases of female and male breast cancer where 
female cancer is below the age of 60 and the male 
cancer is at any age 
 
Bilateral breast cancer or breast and ovarian cancer in the 
same person, can contribute two cases to the above provided 
that both are proven primary carcinomas. 




+ At 50% risk of carrying TP53 because of known 
muta on in parent or sibling, or
 
+ At 50% risk of carrying TP53 in families with a 75% 
prior probability of being due to TP53. These are 




aged <45 years with one of the following in ﬁrst 
degree rela ves: sarcoma (any age), brain tumour, 
early onset of breast cancer, leukaemia, 
adrenocor cal carcinoma, and another tumour in a 
close rela ve which is either cancer aged <45 or 
sarcoma at any age) 
Exclusion: previous breast cancer (include DCIS) 
HIBCRIT 1 study (13) 
N=152 
Bcs=16 
Time frame: 6/2000-1/2007 
Age: 44 [36-60] 
Nega ve tes ng: 30% 
Unknown muta on: 70% 
Women from age 25 who have at least one of the following 
criteria:  
+ Have personal unknown muta onal status but who 
were ﬁrst-degree rela ves of BRCA1 or BRCA2 
muta on carriers  
+ Have a strong family history of breast or ovarian 
cancer, deﬁned as: having three or more events of 
breast or ovarian cancer in ﬁrst- or second-degree 
rela ves in either the maternal or the paternal line. 
These three or more events could have included 
female breast cancer in rela ves younger than 60 
years, ovarian cancer in rela ves at any age, or male 
breast cancer in rela ves at any age.  
Toronto study (15) 
N=100 
BCs=3 
Time frame: 11/1997-6/2009 
Age: 42.5 [36-47] 
Nega ve tes ng: 30% 
Unknown muta on: 70% 
Women who have at least one of the following criteria: 
 
+ First degree rela ve with a BRCA muta on, but not 
tested 
+ Three or more rela ves on the same side of the 
family with breast cancer diagnosed before age 50 or 
ovarian cancer. 
+ Women with a past history of breast cancer were 




















*In the publication of original study, there were 47 breast cancers. Among those, 9 cancers were not 
included due to being screened with only one modality (MRI or mammography) (n=8) and unclear 
information on whether the breast cancer was related to the screening (n=1). There were two breast 
cancers reported as screen detected cancer in the original study. However, they were detected by 
physical examination and missed by MRI or mammography. According to our deﬁnition, those two 
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